12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Linzess: Phase II started

Last October, Astellas began a double-blind, placebo-controlled, dose-escalation, Japanese Phase II trial of oral linaclotide in >500 patients. Linaclotide is approved in the U.S. as Linzess for chronic idiopathic constipation and IBS-C and in the EU as Constella to treat moderate to severe IBS-C. Ironwood is co-developing the...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >